

Clinical Presentation and Outcomes of Pheochromocytomas/Paragangliomas in Neurofibromatosis Type 1

Ahmed Al-Sharefi,¹ Usman Javaid,¹ Petros Perros,¹ John Ealing,^{2,3} Peter Truran,⁴ Sath Nag,⁵ Shafie Kamaruddin,⁶ Kamal Abougilila,⁶ Fiona Cains,³ Lauren Lewis,³ Robert Andrew James¹

1. Department of Endocrinology, The Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle upon-Tyne, UK; 2. Manchester Centre for Clinical Neuroscience, Salford Royal NHS Foundation Trust, Manchester, UK; 3. Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, UK; 4. Department of Endocrine Surgery, The Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK; 5. Department of Endocrinology, The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK; 6. Department of Endocrinology, County Durham and Darlington NHS Foundation Trust, Durham, UK.

DOI: <https://doi.org/10.17925/EE.2019.15.2.95>

Introduction: Patients with neurofibromatosis type 1 (NF1) are at risk of developing pheochromocytomas/paragangliomas (PHEO/PG). Unlike in other familial PHEO/PG syndromes, there are no published guidelines regarding screening in asymptomatic or normotensive patients with NF1. This strategy may be associated with preventable morbidities in those patients who ultimately present with symptomatic PHEO/PG. **Objective:** To describe the mode of presentation and the incidence of adverse clinical outcomes attributed to PHEO/PG in NF1. **Methods:** A retrospective study was performed in a tertiary referral centre in collaboration with a national complex NF1 centre. Hospital records and databases between 1998–2018 were searched. **Results:** Twenty-seven patients with NF1 and PHEO/PG were identified. In all but one, PHEO/PG was diagnosed after NF1. The median age at the time of diagnosis of PHEO/PG was 43 years (range 22–65) and 21/27 (78%) were females. The diagnosis was mostly incidental in 13/27 (48%) while classical PHEO/PG symptoms were found in 15/27 (56%), and hypertension was found in 14/27 (52%) of NF1 patients prior to PHEO/PG diagnosis. No patient had undergone biochemical screening for PHEO/PG. Metastatic disease was evident in 2/27 patients, 8 suffered potentially avoidable complications attributed to PHEO/PG (including two deaths). **Conclusion:** The course of PHEO/PG in NF1 is associated with an unpredictable presentation and potentially avoidable adverse outcomes. We recommend that routine biochemical screening for PHEO/PG should be part of the care package offered to all patients with NF1 by regular measurements of plasma free or urinary fractionated metanephrines starting from early adolescence and repeated every 3 years.

Keywords

Neurofibromatosis-1, pheochromocytoma, paraganglioma, screening, adverse outcomes

Disclosures: Ahmed Al-Sharefi, Usman Javaid, Petros Perros, John Ealing, Peter Truran, Sath Nag, Shafie Kamaruddin, Kamal Abougilila, Fiona Cains, Lauren Lewis and Robert Andrew James have no conflicts of interest to declare in relation to this article.

Review Process: Double-blind peer review.

Compliance with Ethics: This was a retrospective study of hospital records and databases and did not involve any studies with human or animal subjects performed by any of the authors.

Authorship: All named authors meet the criteria of the International Committee of Medical Journal Editors for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.

Received: 16 February 2019

Accepted: 25 April 2019

Citation: *European Endocrinology*. 2019;15(2):95–100

Corresponding Author: Ahmed Al-Sharefi, Department of Endocrinology, Sunderland Royal Hospital, Kayll Road, Sunderland, SR4 7TP UK. E: ahmed.al-sharefi@nhs.net Twitter: @ahmed_alsharefi

Support: No funding was received in the publication of this article.

Pheochromocytomas/paragangliomas (PHEO/PG) are chromaffin cell tumours that can present sporadically or as part of other familial syndromes including hereditary paraganglioma syndromes, multiple endocrine neoplasia 2, von Hippel-Lindau syndrome and neurofibromatosis type 1 (NF1). PHEO/PG are found in about 0.2% of patients with hypertension¹ and in 5% of all cases of adrenal incidentalomas.^{2,3} The vast majority of PHEO/PG produce catecholamines, which are metabolised into metanephrines and 3-MT (methoxytyramine). PHEO/PG are treated with surgical resection followed by lifelong biochemical and radiological screening, especially in those patients at high risk of recurrent and/or metastatic disease.⁴

Although these tumours can occur at any age, they are more prevalent during the fourth to fifth decades⁵ with a diverse clinical presentation that can range from being asymptotically discovered (incidental), to the typical attacks, such as paroxysmal headache, sweating, palpitations/tachycardia,^{1,6} and patients may also present with fatal complications. Indeed, many patients do not have the classic triad of symptoms^{7,8} and around 5–15% of patients can be normotensive.^{6,9,10}

NF1 is an autosomal dominant neuro-cutaneous disorder with an estimated birth incidence of 1 in every 2,500–3,000 individuals.¹¹ The clinical criteria are robust¹² and by using RNA-based assays, mutations in the NF1 can be detected in >95% of those meeting the clinical criteria.¹³ While it is recommended to screen for PHEO/PG in individuals with other predisposing genetic disorders, neither adult nor paediatric NF1 guidelines recommend routine biochemical screening in patients with NF1 unless they are hypertensive or symptomatic.^{14,15} Patients with undiagnosed PHEO/PG are at risk of developing life-threatening cardiovascular complications due to PHEO crises triggered by tumour manipulation, anaesthesia, drugs, pregnancy,¹⁶ or rarely, metastatic disease. Over the last few years, there has been increased attention in the literature to the potential significance and need for biochemical screening in patients with NF1 for PHEO/PG. As asymptomatic and normotensive patients with NF1 are not suitable candidates for screening as per the currently practiced recommendations, the aim of this study was to examine the safety and impact of such

approach on patients with NF1 who ultimately present with PHAEO/PG, by looking into the mode of presentation and the incidence of any adverse outcomes.

Methods

Adult patients with a diagnosis of NF1 and PHAEO/PG were identified via a retrospective search of hospital records from a tertiary referral unit in the north-east of England (The Royal Victoria Infirmary – Newcastle Hospitals NHS Foundation Trust) from 1998–2018. Caldicott approval was obtained prior to data collection. Retrospectively collected data for all resected PHAEO/PG was obtained and matched with a computer-based search for all histologically confirmed PHAEO/PG. Using this approach, it was possible to track those cases of NF1 with PHAEO/PG managed at different hospitals within the region. A parallel computer search on the NF1 register database was performed by the national complex NF1 service based at Manchester Centre of Genomic Medicine.

A diagnosis of NF1 identified by the database search was confirmed by reviewing the clinical records complying with the clinical criteria of NF1 and/or genetic testing. The diagnosis of PHAEO/PG was based on biochemical, radiological and histological criteria. A diagnosis of hypertension was assigned to patients stated to have such a diagnosis or described as being on anti-hypertensive medications. Classical PHAEO symptoms were defined as the presence of any of the following: headaches, palpitations and sweating.^{1,6,17} Review of medical records, including history and examination, was performed retrospectively to identify the presence of any classical symptoms, even in those patients where the diagnosis was found incidentally.

Currently, Liquid chromatography with tandem mass spectrometry assay for measuring plasma metanephrines has been in use since 2010. Prior to this, plasma catecholamines were measured. For urinary metanephrines, liquid chromatography with electrochemical detection method has been in use since at least 2002. Because of the difference in the assays used in other hospitals across the north of England, and to account for the change in the preference for the assays used over time, the interpretations of the biochemical results were unified by adopting the use of a standard score.¹⁸ The standard score can be calculated as below:

Standard score = (current – highest value in the normal range)/highest value in the normal range

Patients' demographics; mode of clinical presentation; biochemical, radiological and histology results; and the occurrence of death, metastases and any adverse complications attributed to hypertensive crisis or circulating catecholamines, were recorded.

Statistical analysis

Analysis of data was carried out using the available statistical package of SPSS-24 (Statistical Packages for Social Sciences version 24). The significance of the difference of different percentages (qualitative data) was tested using Pearson chi-square test (χ^2 -test) with the application of Yate's correction or Fisher's exact test whenever applicable. Statistical significance was considered whenever the p-value was ≤ 0.05 .

Results

Patients demographics

Of 180 patients who had PHAEO/PG resection and 3,715 with NF1, 27 patients with dual diagnosis of NF1 and PHAEO/PG were identified (Table 1). Fifteen of these patients were identified by searching the hospital records with further 12 patients were identified through the NF1

database. All patients had a clinical diagnosis of NF1 before PHAEO was diagnosed except for one patient, in whom genetic testing after PHAEO resection confirmed a pathological NF1 mutation. Two patients were siblings. The mean age at presentation with PHAEO was 43.1 ± 12.7 years (range 22–65) and 78% (n=21) were females.

Mode of presentation

The mode of presentation was incidental (tumours were identified by imaging performed for other indications) in 48% (n=13) of patients, 30% (n=8) of patients presented with symptoms, and 22% (n=6) were identified during investigations for secondary hypertension. Typical PHAEO symptoms were reported in 55% (n=15) (including those patients where the diagnosis was found incidentally) and 52% (n=14) were hypertensive prior to PHAEO/PG diagnosis. No patient had undergone biochemical screening for PHAEO/PG before the later diagnosis was evident.

Diagnosis confirmation

Imaging confirmed the presence of a unilateral adrenal mass in 78% (n=21) of patients, a bilateral adrenal mass in 11% (n=3), and an extra-adrenal location in 11% (n=3). Mean tumour size was 5.0 ± 2.8 cm (range 1.0–13.5). Biochemical results were available in 23/27 patients. All patients had plasma and/or urinary catecholamines elevated with mean standard score for plasma metanephrines (n=20) of 6.6 ± 7.6 (range 0–36), plasma normetanephrines (n=20) 7.5 ± 7.8 (range 0.0–25.6), urinary metanephrines (n=7) 7.5 ± 7.8 (range 0.0–25.6), and urinary normetanephrines (n=6) 6.1 ± 9.7 (range 0.21–25.7). Histology results were available for 23 patients. Adrenal PHAEO was confirmed in 21 patients (of which, two patients had composite PHAEO-ganglioneuroma). Paraganglioma was confirmed histologically in two patients. Another patient with a pelvic neurofibroma was assumed to have intra-fibroma paraganglioma tissue as metanephrines levels normalised after neurofibroma resection. All patients received medical therapy with an appropriate alpha-blockade agent prior to consideration of surgery.

Adverse clinical outcomes

Potentially avoidable complications had occurred in 8/27 of patients at the time of diagnosis of PHAEO/PG (Table 2). Among these eight patients with documented complications, four were hypertensive and only five presented with classical PHAEO/PG related symptoms. Three patients were found to have Takotsubo cardiomyopathy including one patient who presented with acute heart failure and acute lower limb ischemia due to left ventricular thrombus formation needing embolectomy. In another patient there was a 7-year history of anxiety, low mood, and chest pain. The patient received a diagnosis of non-ST elevation myocardial infarction and treated with dual anti-platelet therapy and β receptors blockers for 1 year before subsequent cardiac catheterisation and magnetic resonance imaging showed no evidence of ischemic heart disease. Indeed, the delay in recognising PHAEO in this patient resulted in exposure to the risks of an invasive cardiac procedure as well as the risk of worsening hypertension and bleeding due to the use of β blockers and dual anti-platelet therapy.

Two patients had metastatic disease; one patient received surgical resection followed by chemotherapy while the other patient presented with a fall and multiple fractures with subsequent diagnosis of metastatic PHAEO that was palliatively treated with radionuclide therapy before his death.

Two patients had disease recurrence. Another patient died as a result of post-adrenalectomy stroke and two young females suffered hypertensive crises during pregnancy/after delivery. As compared

Table 1: Data of patients with pheochromocytomas/paragangliomas and neurofibromatosis type 1

Patient ID	Year of diagnosis	Age at presentation	Gender	Mode of presentation	Hypertension	Typical PHAEO/PG symptoms	SSPM	SSPNM	SSUM	SSUNM	Radioactivity	MIBG/PET	Size (cm)	Size2 (cm)	Histopathology	Recurrence	Metastases	FU (years)	Complications
1	2001	52	Female	Symptomatic	Yes	Yes	N/A	N/A	N/A	N/A	Lt adrenal	Lt adrenal	4	N/A	PHAEO	No	No	17	No
2	2001	38	Female	Hypertension	Yes	No	N/A	N/A	N/A	N/A	Lt adrenal	Lt adrenal	3.5	N/A	PHAEO	No	No	17	No
3	2006	36	Female	Symptomatic	Yes	Yes	0	0.7	1.9	0.21	Lt adrenal	Lt adrenal	2.5	N/A	PHAEO	No	No	11	No
4	2006	38	Female	Incidental	No	No	0.01	1.4	0.04	3.7	Lt adrenal	Lt adrenal	3	N/A	PHAEO	No	No	11	No
5	2007	45	Female	Symptomatic	Yes	Yes	7.34	5.4	0	3.75	Ex adrenal	Ex adrenal	4	N/A	PG	No	No	10	No
6	2009	49	Female	Symptomatic	Yes	Yes	7.2	25.6	9.5	25.7	Bilateral	Bilateral	1.6	8	PHAEO	No	No	8	No
7	2010	65	Male	Hypertension	Yes	No	4.14	2.31	4.27	1.67	Rt adrenal	Rt adrenal	4	N/A	PHAEO (composite)	No	No	7	No
8	2014	61	Female	Incidental	No	No	1.2	0	N/A	N/A	Lt adrenal	Lt adrenal	2.4	N/A	PHAEO	No	No	3	Yes
9	2015	34	Female	Hypertension	No	No	36	20	N/A	N/A	Ex adrenal	Ex adrenal	9	N/A	PG	No	No	3	No
10	2016	45	Female	Incidental	No	No	5.7	2.95	N/A	N/A	Rt adrenal	Rt adrenal	8	N/A	PHAEO	No	No	1	No
11	2017	51	Female	Incidental	No	No	1.8	1.93	N/A	N/A	Negative	Negative	2.9	N/A		No	No	1	Yes
12	2017	49	Male	Incidental	Yes	Yes	8.9	2.44	N/A	N/A	Rt adrenal	Rt adrenal	3	N/A	PHAEO	No	No	1	Yes
13	2011	52	Male	Incidental	No	Yes	6.1	20	N/A	N/A	Lt adrenal	Lt adrenal	6	N/A	PHAEO	No	Yes	5	Yes
14	2015	43	Female	Incidental	Yes	Yes	6.8	12	N/A	N/A	Rt adrenal	Rt adrenal	6	N/A	PHAEO (composite)	No	No	3	No
15	2016	63	Female	Incidental	Yes	No	11.1	1.56	N/A	N/A	Rt adrenal	Rt adrenal	5	N/A	PHAEO	No	No	2	No
16	2011	61	Female	Incidental	Yes	Yes	6.7	9	N/A	N/A	Rt adrenal	Rt adrenal	6.1	N/A	PHAEO	Yes	No	2	Yes
17	2017	31	Female	Incidental	No	Yes	6.13	4.3	N/A	N/A	Negative	Negative	4.5	N/A	PHAEO	No	No	1	N/A
18	2011	35	Male	Incidental	No	No	7.7	9.66	N/A	N/A	Rt adrenal	Rt adrenal	4.5	N/A	PHAEO	No	No	7	N/A
19	2008	27	Female	Symptomatic	No	Yes	N/A	N/A	N/A	N/A	Bilateral	Bilateral	N/A	N/A	PHAEO	No	No	11	No
20	2012	36	Male	Hypertension	Yes	Yes	8.8	11.7	N/A	N/A	Bilateral	Bilateral	5	3	PHAEO	No	No	6	N/A
21	2013	59	Female	Symptomatic	No	Yes	N/A	N/A	1.6	N/A	Lt adrenal	Lt adrenal	3.3	N/A	PHAEO	No	Yes	5	Yes
22	2017	24	Male	Incidental	No	Yes	0.31	0.92	N/A	N/A	Lt adrenal	Lt adrenal	13.5	N/A	PHAEO	No	No	1	N/A
23	2001	51	Female	Symptomatic	Yes	Yes	N/A	N/A	N/A	N/A	Rt adrenal	Rt adrenal	N/A	N/A	PHAEO	No	No	17	No
24	1998	29	Female	Hypertension	Yes	No	N/A	N/A	N/A	N/A	Lt adrenal	Lt adrenal	9	N/A	PHAEO	Yes	No	20	Yes
25	1996	25	Female	Symptomatic	No	Yes	N/A	N/A	0.4	1.56	Ex adrenal	Ex adrenal	8	N/A	N/A	No	No	18	No
26	2018	22	Female	Hypertension	Yes	No	4.88	17.3	N/A	N/A	N/A	N/A	5.5	N/A	N/A	No	No	ongoing	Yes
27	2017	42	Female	Incidental	No	No	1.78	1.07	N/A	N/A	Rt adrenal	Rt adrenal	1	N/A	PHAEO	No	No	1	No

BP = blood pressure; Ex = extra; FU = follow up; Lt = left; MIBG/PET = M-iodobenzyl-guanidine/positron emission tomography; PHAEO/PG = pheochromocytomas/paragangliomas; Rt = right; SSPM = standard score for plasma metanephrines; SSUNM = standard score for urinary metanephrines; SSUM = standard score for urinary normetanephrines; n/a: not available or not performed

Table 2: Patients who presented with adverse outcomes/complications

Patient ID	Age	Sex	Hypertensive?	Reported symptoms	Complications
8	61	F	No	Shortness of breath	Takotsubo cardiomyopathy, acute heart failure, acute lower limb ischaemia due left ventricular thrombus
11	51	F	No	None	Takotsubo cardiomyopathy
12	49	M	Yes	Anxiety, recurrent chest pain	Takotsubo cardiomyopathy; Had percutaneous coronary intervention to investigate the chest pain; Received a dual antiplatelet therapy for 1 year for assumed myocardial infarction diagnosis till found to have PHAEO
13	52	M	No	Sweating, palpitations, weight loss	Metastatic spinal disease, received radionuclide treatment and spinal radiotherapy but subsequently died
16	61	F	Yes	Anxiety, palpitations, sweating	Recurrent disease complicated by post-operative stroke and subsequently died
21	59	F	No	Flushing, headaches, palpitations, dizziness	Metastatic lung disease received chemotherapy
24	29	F	Yes	None	Post-partum hypertensive crisis and seizure; Subsequently had a disease recurrence
26	22	F	Yes	None	Hypertensive crisis in pregnancy

F = female; M = male; PHAEO = pheochromocytomas

to patients who did not present with complications, there was no significant statistical difference in age ($p=0.389$), sex ($p=0.214$), tumour size ($p=0.863$), presence of hypertension ($p=0.645$), presence of typical PHAEO symptoms ($p=0.879$), or catecholamines levels ($p=0.498$).

Discussion

Prevalence of PHAEO/PG in NF1

The prevalence of PHAEO/PG in patients with NF1 remains debateable. While the mostly cited prevalence in the literature is 0.1–5.7% based on a retrospective review in 1999 of families with NF1,¹⁹ subsequent studies showed that the prevalence might be higher if patients were screened prospectively. In a prospective study of 156 patients with NF1, the prevalence of PHEO/PG in NF1 was 7.7%.²⁰ An even higher prevalence (14.6%) was reported when 48 consecutive patients with NF1 were screened prospectively.²¹ This indicates that the association between NF1 and PHAEO/PG could have been underestimated in the past.

Mode of Presentation

In the last few years, an increase in the number of patients with PHAEO/PG detected incidentally was evident in those who are normotensive and asymptomatic given the widespread use of advanced imaging modalities and a better understanding of the genetic basis of the disease.^{2,3,8,18,22} In the cohort presented here, PHAEO/PG was discovered incidentally in 48% of subjects with NF1 with a significant percentage of patients diagnosed in the absence of classical symptoms or elevated blood pressure.

While sustained and/or paroxysmal hypertension is a feature of PHAEO in 80–90% of affected individuals, 5–15% of patients could be normotensive at diagnosis.²³ Even with increased circulating catecholamines levels, blood pressure may not be elevated due to multiple factors including catecholamines-induced hypovolemia due to vasoconstriction, the rate of catecholamines inactivation and availability to target cells, the reactivity of vascular smooth muscle, and catecholamines receptor numbers and sensitivity.²⁴ It has been found that chronic exposure to a high level of catecholamines may result in desensitisation of the postjunctional α_1 - and α_2 -adrenergic receptor causing an attenuation to their vasopressor responses.²⁵ In the present study, 14 out of 27 patients (52%) were not known to be hypertensive before the diagnosis of PHAEO/PG.

The classical triad of paroxysmal headache, palpitations and sweating is strongly associated with catecholamines excess and often described as ‘an attack’.¹⁷ However, the disease is still referred to as ‘the great mimic’ as the clinical presentation can be diverse with non-specific signs and symptoms.²⁶ In the present study, 15 out of 27 patients (56%) presented with at least one of the classical symptoms while the remaining patients presented with a variety of other symptoms (Table 1).

Review of the literature

Several studies in the literature have reported heterogeneity in the presentation of PHAEO/PG in NF1 (Table 3^{18,20,21,27–31}) and questioned the significance of screening.

In a large retrospective study of PHAEO/PG in NF1 population, Gruber et al. studied 41 patients from the Mayo clinic database between 1959–2015 and found that the diagnosis of PHAEO/PG was mostly incidental over the last 2 decades, with only three patients (7.3%) who were found through biochemical case detection.¹⁸ Moreover, the authors observed that all cases of bilateral, recurrent and metastatic diseases occurred in women. In their study, the authors recommended biochemical screening for PHAEO/PG in all patients with NF1 at an early age (age 10–14 years) with a repeat evaluation every 3 years and before elective surgical interventions and conception.

In another study, Képénékian et al. prospectively screened 156 patients with NF1 using a combination of urinary metanephrines and abdominal imaging and subsequently found 12 cases of PHAEO/PG.²⁰ Without this prospective methodology, only two patients out of the 12, could have been diagnosed using the current approach of electing only symptomatic and hypertensive patients for screening. In this study, the authors suggested initiating screening every 4–5 years after 40 years of age.

Furthermore, significant adverse outcomes have been described in a cohort of NF1 patients who were ultimately found to have PHAEO/PG. Petr et al. recently studied 17 patients with NF1/PHAEO/PG; two patients were found to have metastatic disease and six suffered cardiovascular crises, especially during surgical procedures and/or delivery.³¹ Butz et al. investigated the peri-operative outcomes of PHAEO/PG resection in a cohort of patients at the Mayo clinic from 2000–2016 and found that patients with NF1 suffer the worse intraoperative hemodynamic

Table 3: Published studies reporting cases of neurofibromatosis type 1 and pheochromocytomas/paragangliomas since 2000

Author (year)	Type of study	Patients with NF1 and PHAEO/PG	Asymptomatic/non-classical symptoms (%)	No. of normotensive patients	No. of malignant tumours	Comments
Amar et al. 2005 ²⁷	Prospective	13	-	-	1	
Bausch et al. 2006 ²⁸	Retrospective	25	-	-	3	
Zinnamosca et al. 2011 ²¹	Prospective	7	3	1	-	
Shinall et al. 2014 ²⁹	Retrospective	6	3	5		
Képénékian et al. 2016 ²⁰	Prospective	12	10	10		Six patients had secretory PHAEO. Only two patients were symptomatic and hypertensive
Moramarco et al. 2017 ³⁰	Retrospective	9	7	3		
Gruber et al. 2017 ¹⁸	Retrospective	41			3	Twenty-one patients presented with symptoms including paroxysmal hypertension, headaches, palpitation and hyperhidrosis
Petr et al. 2018 ³¹	Retrospective	17	-	8	2	

Studies included are those reporting at least five patients with NF1/PHAEO.

NF1 = neurofibromatosis type 1; PHAEO/PG = pheochromocytomas/paragangliomas

course and more severe postoperative complications, as compared to other PHAEO/PG genetic syndromes.³² This was felt due to larger tumour size and higher levels of catecholamines as compared to other familial PHAEO/PG syndromes where more strict and timely screening is applied.

A recent review of all published isolated case reports of PHAEO/PG in patients with NF1 found at least 73 cases; 36/73 did not present with any of classical symptoms while 27/73 were normotensive at the time of PHAEO/PG diagnosis.³³ Furthermore, it was found that 31/73 of patients presented with life-threatening complications and interestingly, the majority were relatively young (age <40 years). These findings, in contrast to Képénékian et al.,²⁰ would favour considering screening at an earlier age.

Current practice

The currently practiced guidelines for the management of NF1 recommend that patients with NF1 should have a specialist clinic visit once a year where clinical evaluation is performed and blood pressure is measured given the association with renal artery stenosis and PHAEO.¹⁴ According to the American College of Medical Genetics and Genomics, only patients with NF1 and hypertension, aged ≥ 30 years, who are pregnant, and/or symptomatic should be considered for biochemical or imaging screening given the lack of any randomised studies on the efficacy of biochemical or imaging screening to detect PHAEO in asymptomatic patients with NF1.³⁴ The presumed perception of an infrequent occurrence of PHAEO/PG in NF1 could also be another reason for the lack of an agreed consensus with regards to screening asymptomatic patients.

However, the value of screening needs to be reconsidered in light of the emerging findings from retrospective and prospective studies over the last few years. The currently perceived low risk of PHAEO/PG in NF1 is likely to be underestimated as most of our knowledge is derived from retrospective case series with a small number of patients, albeit higher prevalence was evident on prospective case detection.^{20,21} In addition, it is clear that the current case detection strategy fails to identify those patients who are incidentally confirmed to have PHAEO/PG. Finally, the observations presented in the current study, in addition to the evidence provided from recent studies,^{27,28} suggest that NF1

subjects are at risk of developing catastrophic sequelae upon under-recognition of PHAEO/PG.

The literature and these findings suggest that majority of patients with NF1 who were ultimately found to have PHAEO/PG, reported non-specific symptoms and had been through multiple consultations, extensive investigations, and invasive procedures over the years before the diagnosis of PHAEO/PG was reached. Besides the risk of catastrophic complications that may eventually arise, this patient pathway generates additional medical costs, hospital visits and uncertainty, which negatively impacting the patient's mental and physical wellbeing. In view of the above, it may be argued that routine screening could be safe and cost-effective in reducing the burden, morbidity and mortality in patients with NF1. A well-designed randomised controlled trial or a population based-study is necessary to address this important question.

Limitations and strengths

This study is retrospective and therefore the strength of evidence is relatively low. The NF1 register may not be representative of the true prevalence of NF1, a potential source of bias. Also, it was challenging to track all the medical records and obtain full clinical information as many patients were treated in different units across northern England. Despite those caveats, to our knowledge, this series represents the largest European cohort of NF1 and PHAEO/PG and one of the few to look into the adverse clinical outcomes over the last 20 years.

Conclusion

Relying on symptoms and blood pressure status to decide if screening for PHAEO/PG is needed in patients with NF1 may be associated with unnecessary risk and avoidable harm. We recommend measuring urinary or plasma metanephrines at an early age (10–14 years) and repeating those measurements every 3 years in all patients with NF1 regardless of the way they present. Such an approach is less periodic as compared to other hereditary PHAEO/PG syndromes where frequent surveillance is needed and this can be conceptualised in light of the lower prevalence, penetrance rate and incidence of multifocal disease in NF1.^{32,34–36} Subsequent prospective studies examining and comparing the clinical outcomes of routine biochemical screening versus the current surveillance practice in the NF1 population are warranted. □

1. Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience. *Medicine (Baltimore)*. 1991;70:46–66.
2. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. *J Clin Endocrinol Metab*. 2000;85:637–44.
3. Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. *Endocr Rev*. 2004;25:309–40.
4. Plouin P, Amar L, Dekkers OM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. *Eur J Endocrinol*. 2016;174:G1–10.
5. Guerrero MA, Schreinemakers JM, Vriens MR et al. Clinical spectrum of pheochromocytoma. *J Am Coll Surg*. 2009;209:727–32.
6. Bravo EL. Pheochromocytoma: new concepts and future trends. *Kidney Int*. 1991;40:544–56.
7. Kudva YC, Young WF Jr, Thompson GB et al. Adrenal incidentaloma: An important component of the clinical presentation spectrum of benign sporadic adrenal pheochromocytoma. *The Endocrinologist*. 1999;9:77–80.
8. Baguet JP, Hammer L, Mazzucco TL, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. *Eur J Endocrinol*. 2004;150:681–86.
9. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. *JAMA*. 2004;292:943–51.
10. Manger WM, Gifford RW. Pheochromocytoma. *J Clin Hypertens (Greenwich)*. 2002;4:62–72.
11. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. *Pediatrics*. 2009;123:124–33.
12. Conference Statement. National Institutes of Health Consensus Development Conference. *Arch Neurol*. 1988;45:575–8.
13. Evans DG, Bowers N, Burkitt-Wright E, et al. Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only. *EBioMedicine*. 2016;7:212–20.
14. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *J Med Genet*. 2007;44:81–8.
15. Hersh JH, American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. *Pediatrics*. 2008;121:633–42.
16. Riestler A, Weismann D, Quinkler M, et al. Life-threatening events in patients with pheochromocytoma. *Eur J Endocrinol*. 2015;173:757–64.
17. Soltani A, Pourian M, Davani BM. Does this patient have Pheochromocytoma? a systematic review of clinical signs and symptoms. *J Diabetes Metab Disord*. 2016;15:6.
18. Gruber L, Erickson N, Babovic-Vuksanovic D, et al. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. *Clin Endocrinol (Oxf)*. 2017;86:141–9.
19. Walther MM, Herring J, Enquist E, et al. Von Recklinghausen's disease and pheochromocytomas. *J Urol*. 1999;162:1582–6.
20. Képénékian L, Moggetti T, Lifante JC, et al. Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1. *Eur J Endocrinol*. 2016;175:335–44.
21. Zinnamosca L, Petramala L, Costeta D et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. *Arch Dermatol Res*. 2011;303:317–25.
22. Bryant J, Farmer J, Kessler L, et al. Pheochromocytoma: the expanding genetic differential diagnosis. *J Natl Cancer Inst*. 2003;95:1196–204.
23. Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. *Endocrinol Metab Clin North Am*. 2011;40:295–311.
24. Agrawal A, Gupta S, Mishra AK, et al. Normotensive pheochromocytoma: institutional experience. *World J Surg*. 2005;29:1185–8.
25. Tsujimoto G, Honda K, Hoffman BB, et al. Desensitization of post junctional $\alpha 1$ - and $\alpha 2$ -adrenergic receptor mediated vasopressor responses in rats harbouring pheochromocytoma. *Circ Res*. 1987;61:86–98.
26. Cohen D, Fraker D, Townsend R. Lack of symptoms in patients with histologic evidence of pheochromocytoma. *Ann N Y Acad Sci*. 2006;1073:47–51.
27. Amar L, Bertherat J, Baudin E, et al. Genetic testing on pheochromocytoma or functional paraganglioma. *J Clin Oncol*. 2005;23:8812–8.
28. Bausch B, Borozdin W, Hartmut PH. Clinical and genetic characteristic of neurofibromatosis type 1 and pheochromocytoma. *N Engl J Med*. 2006;354:2729–37.
29. Shinall MC, Solorzano CC. Pheochromocytoma in neurofibromatosis type 1: when it should be suspected? *Endocr Pract*. 2014;20:792–6.
30. Moramarco J, El Ghorayeb N, Dumast N, et al. Pheochromocytoma are diagnosed incidentally and at older age in neurofibromatosis type 1. *Clin Endocrinol (Oxf)*. 2017;86:332–9.
31. Petr EJ, Else T. Pheochromocytoma and paraganglioma in neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening. *Clin Diabetes Endocrinol*. 2018;4:15.
32. Butz JJ, Yan Q, McKenzie TJ, et al. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1. *Surgery*. 2017;162:1259–69.
33. Al-Sharefi A, Perros P, James RA. Phaeochromocytomas/paragangliomas and adverse clinical outcomes in patients with neurofibromatosis type 1. *Endocr Connect*. 2018;7:R254–9.
34. Stewart DR, Korf BR, Nathanson KL, et al. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2018;20:671–82.
35. Welander J, Soderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. *Endocr Relat Cancer*. 2011;18:253–76.
36. Auffroid RD, Ramakant P, Sadowski SM, et al. Pheochromocytoma screening initiation and frequency in von Hippel-Lindau syndrome. *J Clin Endocrinol Metab*. 2015;100:4498–504.